SCHEMBL9419622

SCHEMBL9419622

CCN(CC)CCCCN1c2ccccc2Oc2ccccc21

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 2/20 0.78
MEN1 O00255 1/20 0.78
KMT2A Q03164 1/20 0.78
TDP1 Q9NUW8 1/20 0.78
SIGMAR1 Q99720 2/20 0.55
SMPD1 P17405 2/20 0.48
BCHE P06276 2/20 0.45
ACHE P22303 2/20 0.45
MAOB P27338 2/20 0.45
P2RX4 Q99571 2/20 0.44
SLC6A4 P31645 3/20 0.43
SLC6A2 P23975 1/20 0.43
HRH1 P35367 1/20 0.43
ALDH1A1 P00352 2/20 0.43
ALOX15 P16050 2/20 0.43
KDM4E B2RXH2 1/20 0.43
HPGD P15428 1/20 0.43
HSD17B10 Q99714 1/20 0.43
POLB P06746 1/20 0.43
P2RX1 P51575 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9419633 0.95 PIM1 (0.71) PIM1MEN1KMT2ATDP1SIGMAR1
SCHEMBL29767032 0.88 MEN1 (1.00) PIM1MEN1KMT2ATDP1SIGMAR1
SCHEMBL2269389 0.88 MEN1 (1.00) PIM1MEN1KMT2ATDP1SIGMAR1
Hydrochloric Acid SCHEMBL1559590 0.87 MEN1 (0.98) PIM1MEN1KMT2ATDP1SIGMAR1
Hydrochloric Acid SCHEMBL29358850 0.87 MEN1 (0.98) PIM1MEN1KMT2ATDP1SIGMAR1
SCHEMBL15496911 0.87 MEN1 (0.98) PIM1MEN1KMT2ATDP1SIGMAR1
SCHEMBL8211943 0.84 KMT2A (0.59) PIM1MEN1KMT2ATDP1SIGMAR1
SCHEMBL6106184 0.84 MEN1 (0.93) PIM1MEN1KMT2ATDP1SIGMAR1
SCHEMBL5953850 0.82 MEN1 (0.55) PIM1MEN1KMT2ATDP1SIGMAR1
SCHEMBL13305235 0.81 MEN1 (0.65) PIM1MEN1KMT2ATDP1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108697735-A Method for preparing cells for adoptive T cell therapy 希望之城公司 2018-10-23 CN claimed
US-5371081-A Useful in potentiating the cytotoxic effect of chemotherapeutic agents ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 1994-12-06 US claimed
WO-1993003729-A1 N-SUBSTITUTED PHENOXAZINES FOR TREATING MULTIDRUG RESISTANT CANCER CELLS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-03-04 WO claimed
CN-117425476-A Boric acid compounds, compositions and methods 塔夫茨大学的受托人 2024-01-19 CN disclosed
CN-116981479-A FAP-activated radiation therapy diagnostic method and use relating thereto 塔夫茨大学信托人 2023-10-31 CN disclosed
CN-115697413-A Radiopharmaceuticals and imaging agents targeting FAP and uses related thereto 塔夫茨大学信托人 2023-02-03 CN disclosed
CN-108697735-A Method for preparing cells for adoptive T cell therapy 希望之城公司 2018-10-23 CN disclosed
US-20160002222-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2016-01-07 US disclosed
US-20160002222-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2016-01-07 US disclosed
US-9073916-B2 Prodrug forms of kinase inhibitors and their use in therapy AUCKLAND UNISERVICES LIMITED (NZ) 2015-07-07 US disclosed
US-9073916-B2 Prodrug forms of kinase inhibitors and their use in therapy AUCKLAND UNISERVICES LIMITED (NZ) 2015-07-07 US disclosed
US-9012217-B2 Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2015-04-21 US disclosed
US-9012217-B2 Benzimidazole compounds differentiate a mammalian stem cell into mesodermal or cardiomyocyte cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2015-04-21 US disclosed
US-20120077811-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2012-03-29 US disclosed
US-20120077811-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2012-03-29 US disclosed
WO-2010104406-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY AUCKLAND UNISERVICES LIMITED (NZ) 2010-09-16 WO disclosed
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-06-24 US disclosed
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) 2010-06-24 US disclosed
US-5371081-A Useful in potentiating the cytotoxic effect of chemotherapeutic agents ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 1994-12-06 US disclosed
WO-1993003729-A1 N-SUBSTITUTED PHENOXAZINES FOR TREATING MULTIDRUG RESISTANT CANCER CELLS RESEARCH CORPORATION TECHNOLOGIES, INC. (US) 1993-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077811-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY NTRK3, TK1, TNNI3K PIM1 610/4885MEN1 3882/4885KMT2A 1235/4885
US-20100159596-A1 SMALL MOLECULE COMPOUNDS FOR STEM CELL DIFFERENTIATION RCOR3, BRD3, BRPF3 PIM1 3277/4885MEN1 1570/4885KMT2A 1143/4885
US-20160002222-A1 PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY NTRK3, TK1, TNNI3K PIM1 712/4885MEN1 3948/4885KMT2A 1810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.